Robert Williamson
Director/Board Member at PERSPECTIVE THERAPEUTICS, INC.
Net worth: 407 485 $ as of 2024-03-30
Profile
Robert F.
Williamson is the founder of LaSalle Venture Advisers, founded in 2002, and Aegle Therapeutics Corp., founded in 2013, where he holds the title of Chief Financial Officer & Director.
Currently, he is the President, Chief Executive Officer & Director at Sidecar Therapeutics, Inc., a Director at Clarke Industrial Engineering, Inc., an Independent Director at Perspective Therapeutics, Inc., the President, Chief Operating Officer & Director at Triumvira Immunologics USA, Inc., and a Member-Coulter Oversight Board at the University of Miami.
In his former positions, he served as the Chief Executive Officer & Director at Arriva Pharmaceuticals, Inc., Acting Chief Executive Officer at BrainCells, Inc., Chief Executive Officer at ATXCo, Inc., Chief Executive Officer & Director at PharmAkea, Inc., President, Chief Executive Officer & Director at BioTheryX, Inc., Executive Chairman at Strategic Enzyme Applications, Inc., Executive Chairman at HAYA Therapeutics SA, Independent Director at Pharmasset, Inc., Director at TBG Diagnostics Ltd., Director at IsoRay, Inc., Director at Viewpoint (US), President & Chief Operating Officer at DoubleTwist, Inc., Partner at The Boston Consulting Group, Inc., President & Chief Operating Officer at EOS Biotechnology, Inc., Research Assistant at the Federal Reserve System, and Chief Financial Officer at Oncomyx Therapeutics, Inc. He obtained his undergraduate degree from Pomona College and an MBA from Stanford University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-01 | 342,424 ( 0.06% ) | 407 485 $ | 2024-03-30 |
Robert Williamson active positions
| Companies | Position | Start |
|---|---|---|
| PERSPECTIVE THERAPEUTICS, INC. | Director/Board Member | 2023-02-02 |
Sidecar Therapeutics, Inc.
 Sidecar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sidecar Therapeutics, Inc. operates as a biotechnology and pharmaceutical company. It focuses on drug development for fibrotic disease. The company was founded in 2016 and is headquartered in San Diego, CA. | Chief Executive Officer | - |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services University of Miami (Florida) is a private research university with students from around the world that is focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. The university was founded in 1925 and it is headquartered in Coral Gables, FL. | Corporate Officer/Principal | - |
Triumvira Immunologics USA, Inc.
 Triumvira Immunologics USA, Inc. Miscellaneous Commercial ServicesCommercial Services Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018. | President | 2022-08-31 |
Aegle Therapeutics Corp.
 Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Founder | 2012-12-31 |
Clarke Industrial Engineering, Inc.
 Clarke Industrial Engineering, Inc. Industrial MachineryProducer Manufacturing Clarke Industrial Engineering, Inc. manufactures shutter valves. It specializes in gas lift, gas compression, separators, refinery valves, and tank valves. The company was founded by Kyle Daniels in 2011 and is headquartered in North Kingstown, RI. | Director/Board Member | - |
| LaSalle Venture Advisers | Founder | 2012-10-01 |
Former positions of Robert Williamson
| Companies | Position | End |
|---|---|---|
HAYA Therapeutics SA
 HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Chairman | 2022-09-13 |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Director of Finance/CFO | 2022-08-31 |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Robert Williamson
| Pomona College | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PERSPECTIVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 21 |
|---|---|
DoubleTwist, Inc.
 DoubleTwist, Inc. Miscellaneous Commercial ServicesCommercial Services Doubletwist, Inc. provides genomic information and bioinformatics analysis technologies. The company is headquartered in Oakland, CA. | Commercial Services |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
BrainCells, Inc.
 BrainCells, Inc. Pharmaceuticals: MajorHealth Technology BrainCells Inc. discovers and develops drugs. The company was founded by Fred H. Gage and Harry F. Hixson, Jr. in 2003 and is headquartered in San Diego, CA. | Health Technology |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
PharmAkea, Inc.
 PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | Health Technology |
Clarke Industrial Engineering, Inc.
Clarke Industrial Engineering, Inc. Industrial MachineryProducer Manufacturing Clarke Industrial Engineering, Inc. manufactures shutter valves. It specializes in gas lift, gas compression, separators, refinery valves, and tank valves. The company was founded by Kyle Daniels in 2011 and is headquartered in North Kingstown, RI. | Producer Manufacturing |
TBG Diagnostics Ltd.
 TBG Diagnostics Ltd. Pharmaceuticals: MajorHealth Technology TBG Diagnostics Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It operates through the InVitro Diagnostics segment, which involves in the research of biological drugs and the retail and wholesale of veterinary drugs. The company was founded on September 26, 1989 and is headquartered in Melbourne, Australia. | Health Technology |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
EOS Biotechnology, Inc.
 EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
| Federal Reserve System | Government |
IsoRay, Inc.
 IsoRay, Inc. Medical SpecialtiesHealth Technology IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA. | Health Technology |
| LaSalle Venture Advisers | |
Strategic Enzyme Applications, Inc.
 Strategic Enzyme Applications, Inc. Chemicals: SpecialtyProcess Industries Strategic Enzyme Applications, Inc. engaged in organic chemical manufacturer company. The company was headquartered in San Diego, CA. | Process Industries |
Sidecar Therapeutics, Inc.
Sidecar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sidecar Therapeutics, Inc. operates as a biotechnology and pharmaceutical company. It focuses on drug development for fibrotic disease. The company was founded in 2016 and is headquartered in San Diego, CA. | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Technology Services |
ATXCo, Inc.
 ATXCo, Inc. Pharmaceuticals: OtherHealth Technology ATXCo, Inc. develops clinical programs for the inhibition of fibrotic diseases. Its core asset is PAT-409, a Phase I ready autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF), NASH (nonalcoholic steatohepatitis), PBC (primary biliary cholangitis), scleroderma and chronic kidney disease. The company is headquartered in San Diego, CA. | Health Technology |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Health Technology |
| Viewpoint (US) | |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
Triumvira Immunologics USA, Inc.
Triumvira Immunologics USA, Inc. Miscellaneous Commercial ServicesCommercial Services Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018. | Commercial Services |
- Stock Market
- Insiders
- Robert Williamson